Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Down 3.8% - Here's What Happened

Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) were down 3.8% during mid-day trading on Monday . The company traded as low as $20.55 and last traded at $20.52. Approximately 29,466 shares were traded during mid-day trading, a decline of 87% from the average daily volume of 226,296 shares. The stock had previously closed at $21.33.

Wall Street Analysts Forecast Growth

DNTH has been the topic of several recent analyst reports. HC Wainwright restated a "buy" rating and issued a $40.00 target price on shares of Dianthus Therapeutics in a research note on Wednesday, March 12th. TD Cowen assumed coverage on Dianthus Therapeutics in a research note on Friday, December 20th. They set a "buy" rating on the stock. Guggenheim reiterated a "buy" rating and set a $84.00 price objective on shares of Dianthus Therapeutics in a report on Wednesday, March 12th. Raymond James upgraded Dianthus Therapeutics to a "moderate buy" rating in a report on Thursday, December 12th. Finally, Wedbush reissued an "outperform" rating and set a $36.00 price target on shares of Dianthus Therapeutics in a research report on Wednesday, March 12th. Eight research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Buy" and a consensus price target of $52.14.

Dianthus Therapeutics Stock Down 4.6 %

The firm has a market cap of $576.85 million, a PE ratio of -7.80 and a beta of 1.82. The company has a 50-day simple moving average of $22.14 and a two-hundred day simple moving average of $24.65.

Remove Ads

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last posted its earnings results on Tuesday, March 11th. The company reported ($0.81) earnings per share for the quarter, topping the consensus estimate of ($0.85) by $0.04. The firm had revenue of $1.33 million during the quarter, compared to the consensus estimate of $1.40 million. Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. As a group, equities analysts predict that Dianthus Therapeutics, Inc. will post -2.61 earnings per share for the current year.

Institutional Investors Weigh In On Dianthus Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of DNTH. FMR LLC boosted its stake in shares of Dianthus Therapeutics by 0.8% in the 4th quarter. FMR LLC now owns 4,439,281 shares of the company's stock valued at $96,776,000 after purchasing an additional 36,133 shares in the last quarter. Octagon Capital Advisors LP lifted its holdings in Dianthus Therapeutics by 20.8% in the 4th quarter. Octagon Capital Advisors LP now owns 2,110,167 shares of the company's stock worth $46,002,000 after buying an additional 363,500 shares during the period. TCG Crossover Management LLC purchased a new stake in Dianthus Therapeutics in the fourth quarter worth $32,735,000. Braidwell LP boosted its stake in shares of Dianthus Therapeutics by 144.4% during the 4th quarter. Braidwell LP now owns 1,206,589 shares of the company's stock valued at $26,304,000 after purchasing an additional 712,902 shares in the last quarter. Finally, Alliancebernstein L.P. boosted its position in Dianthus Therapeutics by 13.4% during the 4th quarter. Alliancebernstein L.P. now owns 1,159,776 shares of the company's stock valued at $25,283,000 after acquiring an additional 136,633 shares in the last quarter. 47.53% of the stock is owned by hedge funds and other institutional investors.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.